Profile data is unavailable for this security.
About the company
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
- Revenue in USD (TTM)806.12k
- Net income in USD-53.12m
- Incorporated2006
- Employees82.00
- LocationCorMedix Inc300 Connell Drive, Suite 4200BERKELEY HEIGHTS 07922United StatesUSA
- Phone+1 (908) 517-9500
- Fax+1 (302) 636-5454
- Websitehttps://cormedix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals Inc | 130.30m | -14.23m | 242.11m | 147.00 | -- | -- | -- | 1.86 | -0.8136 | -0.8136 | 7.45 | -1.70 | 1.06 | 1.05 | 5.24 | 886,401.40 | -11.59 | -28.82 | -19.93 | -47.26 | 92.41 | 97.88 | -10.92 | -35.76 | 1.48 | -1.73 | 2.00 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Scpharmaceuticals Inc | 24.05m | -60.64m | 259.15m | 135.00 | -- | 20.24 | -- | 10.78 | -1.56 | -1.56 | 0.6187 | 0.256 | 0.2678 | 0.6563 | 6.23 | 178,133.30 | -67.52 | -38.23 | -75.77 | -42.31 | 71.15 | -- | -252.18 | -1,360.16 | 3.66 | -13.66 | 0.8121 | -- | -- | -- | -48.79 | -- | -- | -- |
| Sanara Medtech Inc | 72.41m | -6.57m | 280.87m | 107.00 | -- | 6.73 | -- | 3.88 | -0.7788 | -0.7788 | 8.62 | 4.77 | 1.10 | 1.86 | 8.13 | 676,731.00 | -10.16 | -17.73 | -12.08 | -22.07 | 89.73 | 88.08 | -9.23 | -17.13 | 1.49 | -4.88 | 0.2577 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Precigen Inc | 4.39m | -135.38m | 284.12m | 202.00 | -- | 5.82 | -- | 64.73 | -0.5407 | -0.5407 | 0.0176 | 0.1709 | 0.0313 | -- | 4.71 | 21,727.72 | -96.46 | -31.50 | -119.34 | -38.63 | -13.56 | 44.00 | -3,084.55 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Esperion Therapeutics Inc | 277.79m | -98.50m | 329.66m | 240.00 | -- | -- | -- | 1.19 | -0.8758 | -0.8758 | 1.84 | -1.77 | 0.9466 | 0.7763 | 5.49 | 1,157,450.00 | -33.56 | -69.45 | -64.71 | -101.81 | 81.82 | -- | -35.46 | -147.44 | 1.49 | 0.0972 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Emergent Biosolutions Inc | 1.10bn | -587.00m | 353.83m | 1.60k | -- | 0.897 | -- | 0.321 | -11.24 | -11.24 | 21.13 | 7.30 | 0.597 | 2.39 | 4.53 | 688,875.00 | -31.80 | -2.94 | -49.34 | -3.66 | 27.18 | 53.24 | -53.26 | -5.95 | 0.5438 | -1.87 | 0.6906 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Theravance Biopharma Inc | 62.02m | -45.65m | 391.87m | 99.00 | -- | 2.02 | -- | 6.32 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Elite Pharmaceuticals Inc | 66.45m | 19.58m | 398.44m | 64.00 | 19.50 | 6.84 | 18.92 | 6.00 | 0.0191 | 0.0191 | 0.064 | 0.0545 | 0.9892 | 2.91 | 4.98 | 1,038,252.00 | 29.15 | 19.07 | 36.18 | 24.29 | 45.27 | 46.63 | 29.47 | 20.77 | 2.09 | 1.44 | 0.1389 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| CorMedix Inc | 806.12k | -53.12m | 412.25m | 82.00 | -- | 8.83 | -- | 511.40 | -0.9262 | -0.9262 | 0.0141 | 0.8355 | 0.014 | -- | -- | 9,830.73 | -92.57 | -54.84 | -110.35 | -62.32 | -64.79 | 6.18 | -6,589.09 | -18,323.42 | 4.43 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Zevra Therapeutics Inc | 23.99m | -65.75m | 424.10m | 65.00 | -- | 10.42 | -- | 17.68 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Xeris Biopharma Holdings Inc | 181.41m | -59.56m | 436.57m | 377.00 | -- | -- | -- | 2.41 | -0.4215 | -0.4215 | 1.28 | -0.1295 | 0.5493 | 0.7428 | 4.99 | 481,201.60 | -18.04 | -43.60 | -23.57 | -56.57 | 83.72 | 78.23 | -32.83 | -143.08 | 1.69 | -1.59 | 1.09 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 453.33m | 150.00 | -- | 2.62 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Aquestive Therapeutics Inc | 58.36m | -25.72m | 463.49m | 135.00 | -- | -- | -- | 7.94 | -0.3565 | -0.3565 | 0.7874 | -0.3896 | 0.6685 | 2.85 | 7.25 | 432,296.30 | -29.46 | -76.63 | -42.14 | -123.85 | 68.49 | 64.24 | -44.07 | -102.95 | 6.98 | -2.67 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Eyepoint Pharmaceuticals Inc | 50.39m | -86.82m | 476.85m | 121.00 | -- | 2.04 | -- | 9.46 | -1.80 | -1.80 | 1.08 | 4.38 | 0.2016 | 1.10 | 8.18 | 416,454.50 | -34.74 | -40.44 | -47.07 | -47.79 | 91.35 | 83.45 | -172.29 | -186.23 | 4.69 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| SNDL Inc | 672.06m | -83.20m | 527.50m | 2.52k | -- | 0.5812 | -- | 0.7849 | -0.3185 | -0.3185 | 2.56 | 3.42 | 0.5988 | 4.63 | 33.15 | 267,115.60 | -7.67 | -24.44 | -8.32 | -27.94 | 25.04 | 22.49 | -12.82 | -62.17 | 2.98 | -- | 0.1125 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
Data as of Sep 23 2024. Currency figures normalised to CorMedix Inc's reporting currency: US Dollar USD
25.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.22m | 5.86% |
| Nomura Securities Co., Ltd. (Private Banking)as of 31 Mar 2024 | 2.95m | 5.37% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.82m | 5.13% |
| Elliott Investment Management LPas of 31 Mar 2024 | 1.55m | 2.82% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.27m | 2.31% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.11m | 2.02% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 458.63k | 0.83% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 205.86k | 0.38% |
| Barclays Bank Plc (Private Banking)as of 31 Mar 2024 | 181.75k | 0.33% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 160.73k | 0.29% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
